15 Einträge gefunden

1. Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

   1. Guttman-Yassky, Emma
   2. Thaçi, Diamant
   3. Pangan, Aileen L
   4. Hong, H Chih-Ho
   5. Papp, Kim A
   6. Reich, Kristian
   7. Beck, Lisa A

   2020 - Forschungsinformationssystem des UKE
2. Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care

   1. da Silva, Neuza Maria Bernardino
   2. Augustin, Matthias
   3. Langenbruch, Anna Katharina
   4. Mrowietz, Ulrich
   5. Reich, Kristian
   6. Thaçi, Diamant
   7. Boehncke, Wolf-Henning

   2020 - Forschungsinformationssystem des UKE
3. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

   1. Deleuran, Mette
   2. Thaçi, Diamant
   3. Beck, Lisa A
   4. de Bruin-Weller, Marjolein
   5. Blauvelt, Andrew
   6. Forman, Seth
   7. Bissonnette, Robert

   2020 - Forschungsinformationssystem des UKE
4. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

   1. Langley, Richard G B
   2. Reich, Kristian
   3. Strand, Vibeke
   4. Feldman, Steven R
   5. Paul, Carle
   6. Gordon, Kenneth
   7. Warren, Richard B

   2020 - Forschungsinformationssystem des UKE
5. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

   1. Simpson, Eric
   2. Bissonnette, Robert
   3. Eichenfield, Lawrence F
   4. Guttman-Yassky, Emma
   5. King, Brett
   6. Silverberg, Jonathan I
   7. Beck, Lisa A

   2020 - Forschungsinformationssystem des UKE
6. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

   1. Reich, Kristian
   2. Kabashima, Kenji
   3. Peris, Ketty
   4. Silverberg, Jonathan I
   5. Eichenfield, Lawrence F
   6. Bieber, Thomas
   7. Kaszuba, Aleksandra

   2020 - Forschungsinformationssystem des UKE
7. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

   1. Reich, Kristian
   2. Griffiths, Christopher E M
   3. Gordon, Kenneth B
   4. Papp, Kim A
   5. Song, Michael
   6. Randazzo, Bruce
   7. Li, Shu

   2020 - Forschungsinformationssystem des UKE
8. Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care

   1. da Silva, Neuza Maria Bernardino
   2. Augustin, Matthias
   3. Langenbruch, Anna Katharina
   4. Mrowietz, Ulrich
   5. Reich, Kristian
   6. Thaçi, Diamant
   7. Boehncke, Wolf-Henning

   2020 - Forschungsinformationssystem des UKE - frei zugänglich
9. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care

   1. Mrowietz, Ulrich
   2. Sorbe, Christina
   3. Reich, Kristian
   4. Von Kiedrowski, Ralph
   5. Weckbecker, Jörg
   6. Radtke, Marc A
   7. Rustenbach, Stephan J

   2020 - Forschungsinformationssystem des UKE
10. COVID‐19 und Auswirkungen auf dermatologische und allergologische Erkrankungen

    1. Buhl, Timo
    2. Beissert, Stefan
    3. Gaffal, Evelyn
    4. Goebeler, Matthias
    5. Hertl, Michael
    6. Mauch, Cornelia
    7. Reich, Kristian

    2020 - Forschungsinformationssystem des UKE
11. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

    1. Reich, Kristian
    2. Armstrong, April W
    3. Foley, Peter
    4. Song, Michael
    5. Miller, Megan
    6. Shen, Y K
    7. You, Yin

    2020 - Forschungsinformationssystem des UKE
12. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)

    1. Lacour, Jean-Philippe
    2. Bewley, Anthony
    3. Hammond, Edward
    4. Hansen, Jes B
    5. Horne, Laura
    6. Paul, Carle
    7. Reich, Kristian

    2020 - Forschungsinformationssystem des UKE
13. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab

    1. Reich, Kristian
    2. Foley, Peter
    3. Han, Chenglong
    4. McElligott, Sean
    5. Muser, Erik
    6. Li, Nan
    7. Armstrong, April W

    2020 - Forschungsinformationssystem des UKE
14. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

    1. Leonardi, Craig
    2. Reich, Kristian
    3. Foley, Peter
    4. Torii, Hideshi
    5. Gerdes, Sascha
    6. Guenther, Lyn
    7. Gooderham, Melinda

    2020 - Forschungsinformationssystem des UKE
15. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

    1. Armstrong, April
    2. Paul, Carle
    3. Puig, Luis
    4. Boehncke, Wolf Henning
    5. Freeman, Michael
    6. Torii, Hideshi
    7. Papp, Kim

    2020 - Forschungsinformationssystem des UKE